Apple Restores Telegram to App Store After Content Policy Violation 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Jetstar to Charge for Overhead Cabin Bags From February 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
AUSTIN, Texas, March 19, 2018 -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, today announced that its management will provide a corporate overview at the Oppenheimer 28th Annual Healthcare Conference, taking place March 20-21 at the Westin New York Grand Central hotel in New York City.
| Presentation Details | ||
| Date: | Wednesday, March 21 | |
| Time: | 10:20am Eastern Time | |
| Location: | Track 3 | |
About Molecular Templates
Molecular Templates is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases. For additional information, please visit Molecular Templates’ website at www.mtem.com.
Investor Contact:
Andrew McDonald, Ph.D.
[email protected]
646-597-6987
Adam Cutler
Chief Financial Officer
[email protected]
862-204-4006
